Top

Current Diabetes Reports

Published in:

01-09-2019 | Diabetic Retinopathy | Microvascular Complications—Retinopathy (DL Chao and G Yiu, Section Editors)

Scaling Up Teleophthalmology for Diabetic Eye Screening: Opportunities for Widespread Implementation in the USA

Authors: Yao Liu, Alejandra Torres Diaz, Ramsey Benkert

Published in: Current Diabetes Reports | Issue 9/2019

Abstract

Purpose of Review

We discuss opportunities to address key barriers to widespread implementation of teleophthalmology programs for diabetic eye screening in the United States (U.S.).

Recent Findings

Teleophthalmology is an evidence-based form of diabetic eye screening. This technology has been proven to substantially increase diabetic eye screening rates and decrease blindness. However, teleophthalmology implementation remains limited among U.S. health systems. Major barriers include financial concerns as well as limited utilization by providers, clinical staff, and patients. Possible interventions include increasingly affordable camera technology, demonstration of financially sustainable billing models, and engaging key stakeholders.

Summary

Significant opportunities exist to overcome barriers to scale up and promote widespread implementation of teleophthalmology in the USA. Further development of methods to sustain effective increases in diabetic eye screening rates using this technology is needed. In addition, the demonstration of cost-effectiveness in a variety of billing models should be investigated to facilitate widespread implementation of teleophthalmology in U.S. health systems.

National Eye Institute. National Eye Institute fact sheet 2015. https://nei.nih.gov/sites/default/files/nei-pdfs/NEI_Factsheet_July_2015_v2.pdf.

National Eye Institute. Facts about diabetic eye disease. 2015. https://nei.nih.gov/health/diabetic/retinopathy. Accessed 15 April 2019.

American Academy of Ophthalmology Retina/Vitreous Panel. Diabetic retinopathy Preferred Practice Pattern® San Francisco, CA 2017. https://www.aao.org/preferred-practice-pattern/diabetic-retinopathy-ppp-updated-2017.

Canedo JR, Miller ST, Schlundt D, Fadden MK, Sanderson M. Racial/ethnic disparities in diabetes quality of care: the role of healthcare access and socioeconomic status. J Racial Ethn Health Disparities. 2018;5(1):7–14. https://doi.org/10.1007/s40615-016-0335-8.CrossRefPubMed

Mansberger SL, Gleitsmann K, Gardiner S, Sheppler C, Demirel S, Wooten K, et al. Comparing the effectiveness of telemedicine and traditional surveillance in providing diabetic retinopathy screening examinations: a randomized controlled trial. Telemed J E Health. 2013;19(12):942–8. https://doi.org/10.1089/tmj.2012.0313.CrossRefPubMedPubMedCentral

Liew G, Michaelides M, Bunce C. A comparison of the causes of blindness certifications in England and Wales in working age adults (16–64 years), 1999–2000 with 2009–2010. BMJ Open. 2014;4(2). doi:ARTN e004015 https://doi.org/10.1136/bmjopen-2013-004015.

Chasan JE, Delaune B, Maa AY, Lynch MG. Effect of a teleretinal screening program on eye care use and resources. JAMA Ophthalmol. 2014;132(9):1045–51. https://doi.org/10.1001/jamaophthalmol.2014.1051.CrossRefPubMed

Mansberger SL, Sheppler C, Barker G, Gardiner SK, Demirel S, Wooten K, et al. Long-term comparative effectiveness of telemedicine in providing diabetic retinopathy screening examinations: a randomized clinical trial. JAMA Ophthalmol. 2015;133(5):518–25. https://doi.org/10.1001/jamaophthalmol.2015.1.CrossRefPubMedPubMedCentral

Pareja-Rios A, Bonaque-Gonzalez S, Serrano-Garcia M, Cabrera-Lopez F, Abreu-Reyes P, Marrero-Saavedra MD. Tele-ophthalmology for diabetic retinopathy screening: 8 years of experience. Arch Soc Esp Oftalmol. 2017;92(2):63–70. https://doi.org/10.1016/j.oftal.2016.08.006.CrossRefPubMed

10.

Kanjee R, Dookeran RI. Tele-ophthalmology for diabetic retinopathy in Canada-meeting the needs of a growing epidemic. Can J Ophthalmol. 2017;52(Suppl 1):S13–S4. https://doi.org/10.1016/j.jcjo.2017.09.021.CrossRefPubMed

11.

Jani PD, Forbes L, Choudhury A, Preisser JS, Viera AJ, Garg S. Evaluation of diabetic retinal screening and factors for ophthalmology referral in a telemedicine network. JAMA Ophthalmol. 2017;135(7):706–14. https://doi.org/10.1001/jamaophthalmol.2017.1150.CrossRefPubMedPubMedCentral

12.

American Diabetes Association. 10. Microvascular complications and foot care. Diabetes Care. 2017;40(Suppl 1):S88–98. https://doi.org/10.2337/dc17-S013.CrossRef

13.

An J, Niu F, Turpcu A, Rajput Y, Cheetham TC. Adherence to the American Diabetes Association retinal screening guidelines for population with diabetes in the United States. Ophthalmic Epidemiol. 2018;25(3):257–65. https://doi.org/10.1080/09286586.2018.1424344.CrossRefPubMed

14.

Solomon SD, Chew E, Duh EJ, Sobrin L, Sun JK, VanderBeek BL, et al. Diabetic retinopathy: a position statement by the American Diabetes Association. Diabetes Care. 2017;40(3):412–8. https://doi.org/10.2337/dc16-2641.CrossRefPubMedPubMedCentral

15.

Li HK, Horton M, Bursell SE, Cavallerano J, Zimmer-Galler I, Tennant M, et al. Telehealth practice recommendations for diabetic retinopathy, second edition. Telemed J E Health. 2011;17(10):814–37. https://doi.org/10.1089/tmj.2011.0075.CrossRefPubMedPubMedCentral

16.

England PH. Diabetic eye screening: guidance on camera approval. GOV.UK. 2018. https://www.gov.uk/government/publications/diabetic-eye-screening-approved-cameras-and-settings/diabetic-eye-screening-guidance-on-camera-approval.

17.

•• Scanlon PH. The English National Screening Programme for diabetic retinopathy 2003–2016. Acta Diabetol. 2017;54(6):515–25. https://doi.org/10.1007/s00592-017-0974-1. This overview of the English National Screening Program for diabetic retinopathy demonstrates the ability of a nationwide teleophthalmology program to dramatically increase and sustain diabetic eye screening rates. In 2015–2016, the national screening rate in England was 82.8% with 2.14 million screened.CrossRefPubMedPubMedCentral

18.

Cavallerano AA, Conlin PR. Teleretinal imaging to screen for diabetic retinopathy in the Veterans Health Administration. J Diabetes Sci Technol. 2008;2(1):33–9. https://doi.org/10.1177/193229680800200106.CrossRefPubMedPubMedCentral

19.

Daskivich LP, Vasquez C, Martinez C, Jr., Tseng CH, Mangione CM. Implementation and evaluation of a large-scale teleretinal diabetic retinopathy screening program in the Los Angeles County Department of Health Services. JAMA Intern Med 2017;177(5):642–649. doi:https://doi.org/10.1001/jamainternmed.2017.0204.CrossRefPubMedPubMedCentral

20.

Wilson C, Horton M, Cavallerano J, Aiello LM. Addition of primary care–based retinal imaging technology to an existing eye care professional referral program increased the rate of surveillance and treatment of diabetic retinopathy. Diabetes Care. 2005;28(2):318–22. https://doi.org/10.2337/diacare.28.2.318.CrossRefPubMed

21.

Walton OB, IV, Garoon RB, Weng CY, Gross J, Young AK, Camero KA et al. Evaluation of automated teleretinal screening program for diabetic retinopathy. JAMA Ophthalmol. 2016;134(2):204–209. doi:https://doi.org/10.1001/jamaophthalmol.2015.5083.CrossRefPubMed

22.

• Lynch MG, Maa AY. Diagnostic time for teleophthalmic care. JAMA Ophthalmol. 2019. https://doi.org/10.1001/jamaophthalmol.2019.1202. This commentary article describes successful teleophthalmology outcomes from the Veteran’s Health Administration and highlights the importance of expanding this technology for improving access to cost effective care in the USA. CrossRefPubMed

23.

Zimmer-Galler IE, Kimura AE, Gupta S. Diabetic retinopathy screening and the use of telemedicine. Curr Opin Ophthalmol. 2015;26(3):167–72. https://doi.org/10.1097/icu.0000000000000142.CrossRefPubMed

24.

Greenan E, Salim M, Coakley DN, James M. The effect of geodemographic factors on the attendance rates at a regional diabetic retinopathy treatment Centre. Ir J Med Sci. 2019. https://doi.org/10.1007/s11845-019-02009-4.

25.

Silva PS, Aiello LP. Telemedicine and eye examinations for diabetic retinopathy: a time to maximize real-world outcomes. JAMA Ophthalmol. 2015;133(5):525–526. doi:https://doi.org/10.1001/jamaophthalmol.2015.0333.CrossRefPubMed

26.

Owsley C, McGwin G Jr, Lee DJ, Lam BL, Friedman DS, Gower EW, et al. Diabetes eye screening in urban settings serving minority populations: detection of diabetic retinopathy and other ocular findings using telemedicine. JAMA Ophthalmol. 2015;133(2):174–81. https://doi.org/10.1001/jamaophthalmol.2014.4652.CrossRefPubMedPubMedCentral

27.

Ahmed J, Ward TP, Bursell SE, Aiello LM, Cavallerano JD, Vigersky RA. The sensitivity and specificity of nonmydriatic digital stereoscopic retinal imaging in detecting diabetic retinopathy. Diabetes Care. 2006;29(10):2205–9. https://doi.org/10.2337/dc06-0295.CrossRefPubMed

28.

Cavallerano AA, Cavallerano JD, Katalinic P, Tolson AM, Aiello LP, Aiello LM. Use of Joslin Vision Network digital-video nonmydriatic retinal imaging to assess diabetic retinopathy in a clinical program. J Ret Vit Dis. 2003;23(2):215–23.

29.

Cavallerano AA, Cavallerano JD, Katalinic P, Blake B, Rynne M, Conlin PR, et al. A telemedicine program for diabetic retinopathy in a Veterans Affairs Medical Center--the Joslin Vision Network eye health care model. Am J Ophthalmol. 2005;139(4):597–604. https://doi.org/10.1016/j.ajo.2004.10.064.CrossRefPubMed

30.

•• Abràmoff MD, Lavin PT, Birch M, Shah N, Folk JC. Pivotal trial of an autonomous AI-based diagnostic system for detection of diabetic retinopathy in primary care offices. Nature. 2018;1(1):39. https://doi.org/10.1038/s41746-018-0040-6. This prospective observational study, conducted in 10 US primary care clinics, provided the data validating the first FDA-approved autonomous artificial intelligence diagnostic system for diabetic retinopathy screening. The algorithm had an 87.2% sensitivity and 90.7% specificity for diagnosing more than mild diabetic retinopathy (mtmDR) and/or diabetic macular edema in at least one eye. CrossRef

31.

Williams GA, Scott IU, Haller JA, Maguire AM, Marcus D, McDonald HR. Single-field fundus photography for diabetic retinopathy screening: a report by the American Academy of Ophthalmology. Ophthalmology. 2004;111(5):1055–62. https://doi.org/10.1016/j.ophtha.2004.02.004.CrossRefPubMed

32.

•• Liu Y, Zupan NJ, Swearingen R, Jacobson N, Carlson JN, Mahoney JE, et al. Identification of barriers, facilitators and system-based implementation strategies to increase teleophthalmology use for diabetic eye screening in a rural US primary care clinic: a qualitative study. BMJ Open. 2019;9(2):e022594. https://doi.org/10.1136/bmjopen-2018-022594. This qualitative study identified strategies from patients and primary care providers to overcome barriers to teleophthalmology use in a rural US primary care clinic. CrossRefPubMedPubMedCentral

33.

• Silva PS, Horton MB, Clary D, Lewis DG, Sun JK, Cavallerano JD, et al. Identification of diabetic retinopathy and ungradable image rate with ultrawide field imaging in a national teleophthalmology program. Ophthalmology. 2016;123(6):1360–7. https://doi.org/10.1016/j.ophtha.2016.01.043 . This large retrospective, multi-state study found a low ungradable image rate (2.8%) for diabetic retinopathy evaluation using non-mydriatic ultra-wide-field imaging in the Joslin Vision Network and Indian Health Service teleophthalmology programs. CrossRefPubMed

34.

DeBuc DC. The role of retinal imaging and portable screening devices in tele-ophthalmology applications for diabetic retinopathy management. Curr Diabetes Rep. 2016;16(12):132. https://doi.org/10.1007/s11892-016-0827-2.CrossRef

35.

Mohammadpour M, Heidari Z, Mirghorbani M, Hashemi H. Smartphones, tele-ophthalmology, and VISION 2020. Int J Ophthalmol-Chi. 2017;10(12):1909–18. https://doi.org/10.18240/ijo.2017.12.19.CrossRef

36.

Ryan ME, Rajalakshmi R, Prathiba V, Anjana RM, Ranjani H, Narayan KMV, et al. Comparison Among Methods of Retinopathy Assessment (CAMRA) study: smartphone, nonmydriatic, and mydriatic photography. Ophthalmology. 2015;122(10):2038–43. https://doi.org/10.1016/j.ophtha.2015.06.011.CrossRefPubMed

37.

Kim TN, Myers F, Reber C, Loury PJ, Loumou P, Webster D, et al. A smartphone-based tool for rapid, portable, and automated wide-field retinal imaging. Transl Vis Sci Technol. 2018;7(5):21. https://doi.org/10.1167/tvst.7.5.21.CrossRef

38.

Toy BC, Myung DJ, He L, Pan CK, Chang RT, Polkinhorne A, et al. Smartphone-based dilated fundus photography and near visual acuity testing as inexpensive screening tools to detect referral warranted diabetic eye disease. J Ret Vit Dis. 2016;36(5):1000–8. https://doi.org/10.1097/IAE.0000000000000955.CrossRefPubMed

39.

Davila JR, Sengupta SS, Niziol LM, Sindal MD, Besirli CG, Upadhyaya S, et al. Predictors of photographic quality with a handheld nonmydriatic fundus camera used for screening of vision-threatening diabetic retinopathy. Ophthalmologica. 2017;238(1–2):89–99. https://doi.org/10.1159/000475773.CrossRefPubMed

40.

Salongcay RP, Silva PS. The role of teleophthalmology in the management of diabetic retinopathy. APJO. 2018;7(1):17–21. https://doi.org/10.22608/apo.2017479.CrossRefPubMed

41.

Rachapelle S, Legood R, Alavi Y, Lindfield R, Sharma T, Kuper H, et al. The cost-utility of telemedicine to screen for diabetic retinopathy in India. Ophthalmology. 2013;120(3):566–73. https://doi.org/10.1016/j.ophtha.2012.09.002.CrossRefPubMed

42.

Nathoo N, Ng M, Rudnisky CJ, Tennant MT. The prevalence of diabetic retinopathy as identified by teleophthalmology in rural Alberta. Can J Ophthalmol. 2010;45(1):28–32. https://doi.org/10.3129/i09-220.CrossRefPubMed

43.

•• Sharafeldin N, Kawaguchi A, Sundaram A, Campbell S, Rudnisky C, Weis E, et al. Review of economic evaluations of teleophthalmology as a screening strategy for chronic eye disease in adults. Br J Ophthalmol. 2018;102(11):1485–91. https://doi.org/10.1136/bjophthalmol-2017-311452. This systematic review found evidence supporting the cost-effectiveness of teleophthalmology for diabetic retinopathy screening. However, most of the included studies were conducted in research settings, which the authors noted may not accurately reflect the true costs and benefits of teleophthalmology programs used in the real world. CrossRefPubMed

44.

de la Torre-Díez I, López-Coronado M, Vaca C, Aguado JS, de Castro C. Cost-utility and cost-effectiveness studies of telemedicine, electronic, and mobile health systems in the literature: a systematic review. Telemed J E Health. 2015;21(2):81–5. https://doi.org/10.1089/tmj.2014.0053.CrossRefPubMedPubMedCentral

45.

Aoki N, Dunn K, Fukui T, Beck JR, Schull WJ, Li HK. Cost-effectiveness analysis of telemedicine to evaluate diabetic retinopathy in a prison population. Diabetes Care. 2004;27(5):1095–101. https://doi.org/10.2337/diacare.27.5.1095.CrossRefPubMed

46.

Kirkizlar E, Serban N, Sisson JA, Swann JL, Barnes CS, Williams MD. Evaluation of telemedicine for screening of diabetic retinopathy in the Veterans Health Administration. Ophthalmology. 2013;120(12):2604–10. https://doi.org/10.1016/j.ophtha.2013.06.029.CrossRefPubMed

47.

Scotland GS, McNamee P, Philip S, Fleming AD, Goatman KA, Prescott GJ, et al. Cost-effectiveness of implementing automated grading within the national screening programme for diabetic retinopathy in Scotland. Br J Ophthalmol. 2007;91(11):1518–23. https://doi.org/10.1136/bjo.2007.120972.CrossRefPubMedPubMedCentral

48.

Phan A-DT, Koczman JJ, Yung C-W, Pernic AA, Doerr ED, Kaehr MM. Cost analysis of teleretinal screening for diabetic retinopathy in a county hospital population. Diabetes Care. 2014;37(12):e252–e3. https://doi.org/10.2337/dc14-0929.CrossRefPubMed

49.

Brown-Connolly NE, Concha JB, English J. Mobile health is worth it! Economic benefit and impact on health of a population-based mobile screening program in new Mexico. Telemed J E Health. 2014;20(1):18–23. https://doi.org/10.1089/tmj.2013.0080.CrossRefPubMedPubMedCentral

50.

Horton MB, Silva PS, Cavallerano JD, Aiello LP. Operational components of telemedicine programs for diabetic retinopathy. Curr Diabetes Rep. 2016;16(12):128. https://doi.org/10.1007/s11892-016-0814-7.CrossRef

51.

Rathi S, Tsui E, Mehta N, Zahid S, Schuman JS. The current state of teleophthalmology in the United States. Ophthalmology. 2017;124(12):1729–34. https://doi.org/10.1016/j.ophtha.2017.05.026.CrossRefPubMed

52.

American Academy of Ophthalmology. Telehealth Retinal Codes 2019. https://www.aao.org/practice-management/news-detail/teleheath-retinal-codes. Accessed 18 June 2019.

53.

Centers for Medicare & Medicaid Services. Rural health clinic (RHC) and federally qualified health center (FQHC) services Medicare benefit policy manual 2018. https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/downloads/bp102c13.pdf.

54.

Dorsey ER, Topol EJ. State of telehealth. N Engl J Med. 2016;375(2):154–61. https://doi.org/10.1056/NEJMra1601705.CrossRefPubMed

55.

Hussey P, Anderson GF. A comparison of single- and multi-payer health insurance systems and options for reform. Health Policy. 2003;66(3):215–28. https://doi.org/10.1016/s0168-8510(03)00050-2.CrossRefPubMed

56.

McCune D. Understanding HEDIS for ophthalmology. Rev Ophthalmol. 2016. https://www.reviewofophthalmology.com/article/understanding-hedis-for-ophthalmology.

57.

Centers for Medicare & Medicaid Services. Medicare Shared Savings Program | Quality Measure Benchmarks for the 2018 and 2019 Reporting Years 2019.

58.

Modjtahedi BS, Theophanous C, Chiu S, Luong TQ, Nguyen N, Fong DS. Two-year incidence of retinal intervention in patients with minimal or no diabetic retinopathy on telemedicine screening. JAMA Ophthalmol. 2019;137(4):445–8. https://doi.org/10.1001/jamaophthalmol.2018.6912.CrossRefPubMedPubMedCentral

59.

WelchAllyn®. RetinaVue® Care Delivery Model Return on Investment Calculator. 2018. https://www.welchallyn.com/en/other/calculator-mkt.html.

60.

Institute of Medicine.The Role of Telehealth in an Evolving Health Care Environment: Workshop Summary. Washington, DC: The National Academies Press; 2012. https://doi.org/10.17226/13466.

61.

Task Force on Telemedicine in Ophthalmology: American Academy of Ophthalmology. Telemedicine for ophthalmology information statement-2018. 2018. https://www.aao.org/clinical-statement/telemedicine-ophthalmology-information-statement.

62.

(IRIS) IRIS. The IRIS solution at work in your practice http://www.retinalscreenings.com/solution 2019.

63.

Solutions TH. Topcon screen: comprehensive eye-care solution for telophthalmology 2019. https://www.topconhealth.com/screening. 2019.

64.

WelchAllyn®. RetinaVue® Care Delivery Model. 2018. https://www.welchallyn.com/en/microsites/retinavue-care-delivery-model.html.

65.

Holley CD, Lee PP. Primary care provider views of the current referral-to-eye-care process: focus group results. Invest Ophthalmol Vis Sci. 2010;51(4):1866–72. https://doi.org/10.1167/iovs.09-4512.CrossRefPubMed

66.

Liu Y, Swearingen R. Diabetic eye screening: knowledge and perspectives from providers and patients. Current Diabetes Reports. 2017;17(10):94. https://doi.org/10.1007/s11892-017-0911-2.CrossRefPubMedPubMedCentral

67.

Beckles GL, Williamson DF, Brown AF, Gregg EW, Karter AJ, Kim C, et al. Agreement between self-reports and medical records was only fair in a cross-sectional study of performance of annual eye examinations among adults with diabetes in managed care. Med Care. 2007;45(9):876–83. https://doi.org/10.1097/MLR.0b013e3180ca95fa.CrossRefPubMed

68.

Short ME, Goetzel RZ, Pei X, Tabrizi MJ, Ozminkowski RJ, Gibson TB, et al. How accurate are self-reports? Analysis of self-reported health care utilization and absence when compared with administrative data. J Occup Environ Med. 2009;51(7):786–96. https://doi.org/10.1097/JOM.0b013e3181a86671.CrossRefPubMedPubMedCentral

69.

Wisconsin Department of Safety and Professional Services. Wisconsin Enhances Prescription Drug Monitoring Program 2019. https://pdmp.wi.gov/. Accessed 17 May 2019.

70.

Wisconsin Immunization Registry (WIR) [database on the Internet]2019. Available from: https://www.dhfswir.org/PR/portalInfoManager.do. Accessed 17 May 2019.

71.

Conlin PR, Fisch BM, Orcutt JC, Hetrick BJ, Darkins AW. Framework for a national teleretinal imaging program to screen for diabetic retinopathy in Veterans Health Administration patients. JRRD. 2006;43(6):741–7. https://doi.org/10.1682/Jrrd.2005.08.0146.CrossRef

72.

•• Gibson DM. Estimates of the percentage of US adults with diabetes who could be screened for diabetic retinopathy in primary care settings. JAMA ophthalmology. 2019;137:440. https://doi.org/10.1001/jamaophthalmol.2018.6909. This cross-sectional, population-based survey study found that 82.2% of patients with diabetes who had not obtained diabetic eye screening in the preceding 12 months had seen a primary care provider during the same time period. This data provides evidence that primary care visits represent an underutilized opportunity for providing diabetic eye screening using teleophthalmology.CrossRefPubMedPubMedCentral

73.

Pérez GM, Swart W, Munyenyembe JK, Saranchuk P. Barriers to pilot mobile teleophthalmology in a rural hospital in Southern Malawi. Pan Afr Med J. 2014;19:136. https://doi.org/10.11604/pamj.2014.19.136.5196.CrossRefPubMedPubMedCentral

74.

Korot E, Wood E, Weiner A, Sim DA, Trese M. A renaissance of teleophthalmology through artificial intelligence. Eye (lond). 2019;33:861–3. https://doi.org/10.1038/s41433-018-0324-8.CrossRef

75.

Bouskill K, Smith-Morris C, Bresnick G, Cuadros J, Pedersen ER. Blind spots in telemedicine: a qualitative study of staff workarounds to resolve gaps in diabetes management. BMC Health Serv Res. 2018;18(1):617. https://doi.org/10.1186/s12913-018-3427-9.CrossRefPubMedPubMedCentral

76.

Meraya AM, Makeen HA. Self-reported receipt of preventive practices and its associated factors among adults with diabetes in the United States. Prev Med Rep. 2019;14:100857. https://doi.org/10.1016/j.pmedr.2019.100857.CrossRefPubMedPubMedCentral

77.

Maa AY, Wojciechowski B, Hunt KJ, Dismuke C, Shyu J, Janjua R, et al. Early experience with technology-based eye care services (TECS): a novel ophthalmologic telemedicine initiative. Ophthalmology. 2017;124(4):539–46. https://doi.org/10.1016/j.ophtha.2016.11.037.CrossRefPubMed

78.

George SM, Hayes EM, Fish A, Daskivich LP, Ogunyemi OI. Understanding the knowledge gap experienced by U.S. safety net patients in teleretinal screening. AMIA Annual Symposium proceedings AMIA Symposium. 2016;2016:590–9.PubMed

79.

Valikodath NG, Leveque TK, Wang SY, Lee PP, Newman-Casey PA, Hansen SO, et al. Patient attitudes toward telemedicine for diabetic retinopathy. JAMA Ophthalmol. 2017;23(3):205–12. https://doi.org/10.1089/tmj.2016.0108.CrossRefPubMedPubMedCentral

80.

Liu Y, Zupan NJ, Shiyanbola OO, Swearingen R, Carlson JN, Jacobson NA, et al. Factors influencing patient adherence with diabetic eye screening in rural communities: a qualitative study. PLoS One. 2018;13(11):e0206742. https://doi.org/10.1371/journal.pone.0206742.CrossRefPubMedPubMedCentral

81.

Davidson JA. The increasing role of primary care physicians in caring for patients with type 2 diabetes mellitus. Mayo Clin Proc. 2010;85(12 Suppl):S3–4. https://doi.org/10.4065/mcp.2010.0466.CrossRefPubMedPubMedCentral

82.

Hartnett ME, Key IJ, Loyacano NM, Horswell RL, DeSalvo KB. Perceived barriers to diabetic eye care: qualitative study of patients and physicians. Arch Ophthalmol. 2005;123(3):387–91. https://doi.org/10.1001/archopht.123.3.387.CrossRefPubMed

83.

Basch CE, Walker EA, Howard CJ, Shamoon H, Zybert P. The effect of health education on the rate of ophthalmic examinations among African Americans with diabetes mellitus. Am J Public Health. 1999;89(12):1878–82.CrossRefPubMedPubMedCentral

84.

Grohmann B, Espin S, Gucciardi E. Patients’ experiences of diabetes education teams integrated into primary care. Can Fam Physician. 2017;63(2):e128–e36.PubMedPubMedCentral

Title: Scaling Up Teleophthalmology for Diabetic Eye Screening: Opportunities for Widespread Implementation in the USA
Authors: Yao Liu
Alejandra Torres Diaz
Ramsey Benkert
Publication date: 01-09-2019
Publisher: Springer US
Keywords: Diabetic Retinopathy
Care
Diabetic Retinopathy
Telemedicine
Published in: Current Diabetes Reports / Issue 9/2019
Print ISSN: 1534-4827
Electronic ISSN: 1539-0829
DOI: https://doi.org/10.1007/s11892-019-1187-5

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 9/2019

Commentary/Introduction for “Debate on Insulin vs. Non-insulin Use in the Hospital Setting” Articles

Alterations in Beta Cell Identity in Type 1 and Type 2 Diabetes

Genetics of Diabetic Retinopathy

Klinefelter Syndrome and Diabetes

Artificial Intelligence Screening for Diabetic Retinopathy: the Real-World Emerging Application

Extracellular Vesicles in Type 1 Diabetes: Messengers and Regulators

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage